Impact of Underweight after Treatment on Prognosis of Advanced-Stage Ovarian Cancer

Table 2

Comparison of CA-125 and neutrophil to lymphocyte ratio (NLR) among underweight, normal to overweight, and obesity patients according to the treatment time.

BMI	CA-125; (median, U/mL)	NLR; (median)	Confounding factors
			Stage IV disease	Grade 3 disease	Nonserous histology	Suboptimal debulking
At diagnosis
Underweight	185.5	8^*,†	1 (8.3)^*,†	3 (25.0)^*,†	4 (33.3)^*,†	2 (16.7)*
Normal to overweight	865*	9^*,‡	69 (22.3)^*,‡	156 (50.3)^*,‡	69 (22.3)^*,‡	149 (48.1)^*,†
Obesity	912.5*	6.75^†,‡	5 (13.9)^†,‡	21 (58.3)^†,‡	5 (13.9)^†,‡	21 (58.3)^†
𝑃 value	0.04	0.47	0.28	0.14	0.33	0.04
After surgery
Underweight	95.6^*,†	2.58^*,†	6 (18.8)^*,†	15 (46.9)^*,†	3 (9.4)^*,†	10 (32.2)^*,†
Normal to overweight	190.0^*,‡	2.67^*,‡	65 (22.3)^*,‡	146 (50)^*,‡	67 (22.9)^*,‡	143 (49)^*,‡
Obesity	87.5^†,‡	3.14^†,‡	5 (18.5)^†,‡	16 (59.3)^†,‡	5 (17.9)^†,‡	16 (59.3)^†,‡
𝑃 value	0.78	0.23	0.83	0.60	0.29	0.08
After treatment
Underweight	8^*,†	2.15*	5 (17.2)^*,†	13 (44.8)^*,†	6 (20.7)^*,†	10 (34.5)^*,†
Normal to overweight	9^*,‡	1.56^*,†	62 (20.7)^*,‡	148 (50.7)^*,‡	67 (22.4)^*,‡	146 (48.8)^*,‡
Obesity	6.8^†,‡	1.47^†	8 (28.6)^†,‡	18 (66.7)^†,‡	4 (14.3)^†,‡	13 (46.4)^†,‡
𝑃 value	0.21	0.09	0.54	0.27	0.60	0.33

BMI: body mass index; ^*,†,‡no significant difference between two groups with the same symbol.